June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Transcription Factor Brn3b Mediated Neuroprotection in an Ocular Hypertension Rat Model of Glaucoma
Author Affiliations & Notes
  • Dorota L Stankowska
    Department of Cell Biology and Immunology, North Texas Eye Research Institute, UNT Health Science Center, Fort Worth, TX
  • Raghu R Krishnamoorthy
    Department of Cell Biology and Immunology, North Texas Eye Research Institute, UNT Health Science Center, Fort Worth, TX
  • Footnotes
    Commercial Relationships Dorota Stankowska, None; Raghu Krishnamoorthy, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4426. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Dorota L Stankowska, Raghu R Krishnamoorthy, Physiology/Pharmacology (PH); Transcription Factor Brn3b Mediated Neuroprotection in an Ocular Hypertension Rat Model of Glaucoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4426.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Glaucoma is an optic neuropathy commonly associated with elevated intraocular pressure (IOP), leading to optic nerve head (ONH) cupping, axon loss and apoptosis of retinal ganglion cells (RGCs) which could ultimately result in blindness. Brn3b is a class-4 POU domain transcription factor that plays a key role in RGC development, axon outgrowth and pathfinding. Previous studies suggest that a decrease in Brn3b levels occurs in animal models of glaucoma. The goal of this study was to determine if adeno-associated virus-2 (AAV-2)-directed overexpression of the Brn3b protein could have neuroprotective effects following elevated IOP-mediated neurodegeneration.

Methods: IOP was elevated in one eye of Brown Norway rats (Rattus norvegicus), following which the IOP-elevated eyes were intravitreally injected with AAV constructs encoding either GFP (rAAV-CMV-GFP or rAAV-hsyn-GFP) or Brn3b (rAAV-CMV-Brn3b or rAAV-hsyn-Brn3b). Retina sections through the ONH were stained for synaptic plasticity markers and neuroprotection was assessed by retrogradely fluorogold labelled RGC counts and visual acuity tests.

Results: AAV-2-mediated expression of the Brn3b protein in IOP-elevated rat eyes promoted an upregulation of growth associated protein-43 (GAP-43), actin binding LIM protein (abLIM) and acetylated α-tubulin (ac-Tuba) both posterior to the ONH and in RGCs. An increase in Cholera toxin subunit B labeling along the optic nerve axons was found in IOP-elevated rAAV-hsyn-Brn3b injected rat eyes compared to IOP-elevated rAAV-hsyn-GFP injected rat eyes. The RGC counts were significantly higher in IOP-elevated rAAV-hsyn-Brn3b injected rats compared to those of the IOP-elevated rAAV-hsyn-GFP injected rats. Additionally, intravitreal rAAV-hsyn-Brn3b administration significantly restored the visual optomotor response in IOP-elevated rat eyes.

Conclusions: AAV-mediated Brn3b protein overexpression may be a suitable approach for promoting neuroprotection in animal models of glaucoma.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×